Compare Progressive Corp (PGR) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Progressive Corp vs BIO-TECHNE Corp — how do they compare? Progressive Corp trades at $216.26 (market cap $124.88B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: Progressive Corp is far larger — about 11× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays the higher dividend (0.44%). Which is the better fit depends on your goals.
| PGR | TECH | |
|---|---|---|
Market Cap | $124.88B | $11.34B |
Sector | Financials | Health |
52-Week High | $248.80 | $72.48 |
52-Week Low | $190.40 | $43.31 |
Enterprise Value | $133.09B | $11.36B |
Dividend Yield | 0.19% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Progressive (PGR) trades at $214.90, down 1.85% on the day, with a bearish technical signal and neutral oscillators. The stock shows strong fundamentals with a P/E of 10.78, net income margin of 12.85%, and consistent revenue growth from $49.6B in 2022 to $87.6B in 2025. Recent earnings beat expectations in Q2 2026, but Q1 2026 missed. News highlights competition in auto insurance and institutional buying, while July 2026 earnings declined year-over-year due to expenses.
The outlook is mixed: valuation appears attractive with growth potential, but technical weakness and competitive pressures pose risks. Analyst consensus is a buy with a $231.18 price target, though hold ratings dominate at 52.38%. Key risks include expense management and market volatility, while institutional accumulation supports sentiment.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
